TScan Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
TScan Therapeutics R&D Spending Growth & History (TCRX)
TScan Therapeutics's r&d spending was $114.2M for fiscal 2025.
View full TScan Therapeutics company overviewTScan Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $114.2M | $6.8M | +6.33% |
| 2024 | 2024-12-31 | $107.3M | $19.2M | +21.78% |
| 2023 | 2023-12-31 | $88.2M | $28.3M | +47.37% |
| 2022 | 2022-12-31 | $59.8M | $14.9M | +33.07% |
| 2021 | 2021-12-31 | $45.0M | $24.4M | +118.47% |
| 2020 | 2020-12-31 | $20.6M | — | — |
TScan Therapeutics quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $23.4M | −$9.2M | −28.29% |
| Q1 2026 | 2026-03-31 | $21.9M | −$7.9M | −26.47% |
| Q4 2025 | 2025-12-31 | $20.0M | −$9.3M | −31.73% |
| Q3 2025 | 2025-09-30 | $31.7M | $5.4M | +20.66% |
| Q2 2025 | 2025-06-30 | $32.6M | $5.8M | +21.42% |
| Q1 2025 | 2025-03-31 | $29.8M | $4.9M | +19.84% |
| Q4 2024 | 2024-12-31 | $29.4M | $6.9M | +31.01% |
| Q3 2024 | 2024-09-30 | $26.3M | $3.5M | +15.48% |
| Q2 2024 | 2024-06-30 | $26.9M | $5.7M | +26.62% |
| Q1 2024 | 2024-03-31 | $24.9M | $3.1M | +14.13% |
| Q4 2023 | 2023-12-31 | $22.4M | $6.8M | +43.59% |
| Q3 2023 | 2023-09-30 | $22.7M | $7.7M | +51.29% |
| Q2 2023 | 2023-06-30 | $21.2M | $6.7M | +46.45% |
| Q1 2023 | 2023-03-31 | $21.8M | $7.1M | +48.26% |
| Q4 2022 | 2022-12-31 | $15.6M | $3.0M | +23.76% |
| Q3 2022 | 2022-09-30 | $15.0M | $825,000 | +5.81% |
| Q2 2022 | 2022-06-30 | $14.5M | $3.7M | +34.19% |
| Q1 2022 | 2022-03-31 | $14.7M | $7.4M | +100.16% |
| Q4 2021 | 2021-12-31 | $12.6M | — | — |
| Q3 2021 | 2021-09-30 | $14.2M | $8.4M | +144.38% |
| Q2 2021 | 2021-06-30 | $10.8M | $6.3M | +139.92% |
| Q1 2021 | 2021-03-31 | $7.3M | — | — |
| Q3 2020 | 2020-09-30 | $5.8M | — | — |
| Q2 2020 | 2020-06-30 | $4.5M | — | — |
TScan Therapeutics r&d spending trends
Over the last five fiscal years, TScan Therapeutics's r&d spending increased from $20.6M to $114.2M, a change of $93.6M. The latest reported quarter, Q2 2026, shows $23.4M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TScan Therapeutics source filings ↗